FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development

WHY IT MATTERS

This guidance establishes the regulatory pathway that will determine which genome editing therapies can reach patients, potentially accelerating approval timelines for rare genetic diseases currently lacking treatment options.

The FDA released new guidelines to help companies develop gene therapy treatments that use genome editing—a technology that can fix or change faulty genes. These guidelines explain what safety information and testing companies need to provide before the FDA will approve their treatments. This is meant to make it clearer and faster for companies to develop new gene therapies for patients with genetic diseases.

The U.S. Food and Drug Administration today issued a draft guidance for sponsors seeking approval of human gene therapy products involving genome editing technologies.